Vicore Pharma 授予 Nippon Shinyaku 在日本开发和商业化治疗 IPF 的 C21 疗法的独家权利，预付款金额为 1000 万美元，外加里程碑费用和特许权使用费。 Vicore Pharma grants Nippon Shinyaku exclusive rights to develop and commercialize C21 therapy for IPF in Japan, in a USD 10m upfront deal plus milestones and royalties.

Vicore Pharma Holding 是一家专门开发特发性肺纤维化药物的瑞典公司，已与日本领先的制药公司 Nippon Shinyaku 签订独家许可协议，在日本开发和商业化 C21。 Vicore Pharma Holding, a Swedish company specializing in developing drugs for idiopathic pulmonary fibrosis, has entered into an exclusive license agreement with Nippon Shinyaku, a leading Japanese pharmaceutical company, to develop and commercialize C21 in Japan. C21是一种潜在的治疗该疾病的革命性疗法。 C21 is a potentially transformative therapy for the treatment of the disease. Vicore 将收到 1000 万美元的预付款，并有权获得高达 2.75 亿美元的里程碑付款以及分级特许权使用费。 Vicore will receive an upfront payment of USD 10 million and is entitled to up to USD 275 million in milestones, along with tiered royalty payments.